BofA sees limited impact to Eli Lilly’s franchise from Novo’s GLP-1 price update

BofA says that today’s announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm’s view the update is unlikely to have any material impact on the U.S. market. BofA sees today’s move as an attempt to reduce copay/coinsurance costs to patients in settings where that figure is calculated of list/WAC price. More broadly, the firm thinks it’s fair for investors to wonder if/when commercial reimbursement of GLP-1’s could become more commonplace, with BofA cha ...